Bausch Health Companies (BHC) Research & Development (2016 - 2025)
Bausch Health Companies (BHC) has disclosed Research & Development for 17 consecutive years, with $161.0 million as the latest value for Q4 2025.
- Quarterly Research & Development fell 1.23% to $161.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $544.0 million through Dec 2025, down 11.69% year-over-year, with the annual reading at $629.0 million for FY2025, 2.11% up from the prior year.
- Research & Development hit $161.0 million in Q4 2025 for Bausch Health Companies, up from $81.0 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $163.0 million in Q4 2024 to a low of $81.0 million in Q3 2025.
- Historically, Research & Development has averaged $137.9 million across 5 years, with a median of $143.0 million in 2023.
- Biggest five-year swings in Research & Development: increased 22.83% in 2023 and later plummeted 44.52% in 2025.
- Year by year, Research & Development stood at $117.0 million in 2021, then increased by 21.37% to $142.0 million in 2022, then rose by 7.04% to $152.0 million in 2023, then increased by 7.24% to $163.0 million in 2024, then dropped by 1.23% to $161.0 million in 2025.
- Business Quant data shows Research & Development for BHC at $161.0 million in Q4 2025, $81.0 million in Q3 2025, and $159.0 million in Q2 2025.